NDA 215413 · Viiv Hlthcare
Triumeq Pd
Abacavir Sulfate, Dolutegravir Sodium, Lamivudine · Oral · Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Priority reviewLast checked: Nov 19, 2026Latest source record: Oct 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Mar 30, 2022
Approved uses
2
Original approval plus efficacy supplements
Registered trials
239
79 Phase 3, 5 recruiting
FAERS reports
1
1 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HYPERSENSITIVITY REACTIONS, AND EXACERBATIONS OF HEPATITIS B Hypersensitivity Reactions Serious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with abacavir, a component of TRIUMEQ and TRIUMEQ PD (abacavir, dolutegravir, and lamivudine). Patients who carry the HLA ‑ B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir, although hypersensitivity reactions have occurred in patients who do not carry the HLA ‑ B*5701 allele [see Warnings and Precautions ( 5.1 )] . TRIUMEQ and TRIUMEQ PD are contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA ‑ B*5701-positive patients [see Contraindications ( 4 ), Warnings and Precautions ( 5.1 )] . All patients should be screened for the HLA ‑ B*5701 allele prior to initiating therapy with TRIUMEQ or TRIUMEQ PD or reinitiation of therapy...
What it is approved for
From the label in effect Jul 8, 2024.
TRIUMEQ and TRIUMEQ PD are indicated for the treatment of HIV-1 infection in adults and in pediatric patients aged at least 3 months and weighing at least 6 kg. Limitations of Use: TRIUMEQ and TRIUMEQ PD alone are not recommended in patients with resistance‑associated integrase substitutions or clinically suspected integrase strand transfer inhibitor (INSTI) resistance because the dose of dolutegravir in TRIUMEQ and TRIUMEQ PD is insufficient in these subpopulations. See full prescribing information for TIVICAY (dolutegravir). TRIUMEQ and TRIUMEQ PD are a combination of dolutegravir (integrase strand transfer inhibitor [INSTI]), abacavir, and lamivudine (both nucleoside analogue reverse transcriptase inhibitors) indicated for the treatment of HIV-1 infection in adults and in pediatric patients aged at least 3 months and weighing at least 6 kg. ( 1 ) Limitations of Use: TRIUMEQ and TRIUMEQ PD alone are not recommended in patients with resistance-associated integrase substitutions or clinically suspected INSTI resistance because the dose of dolutegravir in TRIUMEQ and TRIUMEQ PD is insufficient in these subpopulations. See the dolutegravir prescribing information. ( 1 )
Mechanism: TRIUMEQ and TRIUMEQ PD are a fixed-dose combination of the HIV‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see Microbiology ( 12.4 )].
Therapeutic areas: Infectious disease and vaccines · Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 15, 2023 Supplement 2 · Efficacy · priority review LabelLetter
- Mar 30, 2022 Original approval · Type 3 - New Dosage Form · priority review LetterLabelReview
1 products under this application
- TRIUMEQ PD · ABACAVIR SULFATE EQ 60MG BASE; DOLUTEGRAVIR SODIUM EQ 5MG BASE; LAMIVUDINE 30MG · TABLET, FOR SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Abacavir" as an intervention, any sponsor and status, largest first.
- Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in PakistanPivotal-lookingRecruiting
Pakistan Institute of Living and LearningAcademic, hospital or other
NCT07015944 · 26,376 participants (planned) · Start Jun 13, 2025 · Primary completion Dec 30, 2028
Drug: Standardised pharmacological treatment (antidepressants) · For: Major Depressive Disorder (MDD); Breast Cancer Survivor
Sites: Karachi, Pakistan
- Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive AdultsPivotal-lookingCompleted
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsResearch network
NCT00118898 · 1,864 participants · Start Sep 2005 · Primary completion Nov 2009
Drug: Abacavir/Lamivudine; Atazanavir and 5 more · For: HIV Infections
Sites: Los Angeles, California; Palo Alto, California; San Diego, California · 52 sites in all
- Clinical Utility Of Genetic Screening For HLA-B*5701, On Susceptibility To Abacavir HypersensitivityPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00340080 · 1,806 participants · Start Apr 2006
Drug: Abacavir · For: HIV Infection
Sites: Darlinghurst, Australia; Miami, Australia; Graz, Austria · 254 sites in all
- A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000922 · 1,710 participants · Primary completion Jan 2003
Drug: Indinavir sulfate; Abacavir sulfate and 6 more · For: HIV Infections
Sites: San Francisco, California; Denver, Colorado; New Haven, Connecticut · 17 sites in all
- Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in AfricaPivotal-lookingCompleted
Medical Research CouncilGovernment (non-federal)
NCT02028676 · 1,206 participants · Start Mar 2007 · Primary completion Mar 2012
Drug: Arm A: ABC+3TC+NNRTI; Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance and 4 more · For: Human Immunodeficiency Virus
Sites: Entebbe, Uganda; Kampala, Uganda; Mulago, Uganda · 4 sites in all
- Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV InfectionPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00013520 · 1,125 participants
Drug: Abacavir sulfate, Lamivudine and Zidovudine; Atazanavir and 8 more · For: HIV Infections
Sites: Birmingham, Alabama; Los Angeles, California; Palo Alto, California · 60 sites in all
- Antiretroviral Therapy for Acute and Chronic HIV InfectionPivotal-lookingRecruiting
SEARCH Research FoundationAcademic, hospital or other
NCT00796263 · 900 participants (planned) · Start May 13, 2009 · Primary completion Jun 2033
Drug: HAART · For: Acute HIV Infection; Chronic HIV Infection
Sites: Bangkok, Thailand
- A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00094367 · 900 participants · Start Jul 2004 · Primary completion Oct 2005
Drug: Abacavir/Lamivudine · For: HIV Infection
Sites: Montgomery, Alabama; Glendale, Arizona; Phoenix, Arizona · 178 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- aggression1
- inappropriate schedule of product administration1
- product dose omission issue1
- product use in unapproved indication1
- psychotic disorder1
- substance use1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review.
Morris SA, Alsaidi AT, Verbyla A, et al. · Clin Pharmacol Ther 2022 · Systematic Review
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Equivalence Trial
- Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.
Musiime V, Bwakura-Dangarembizi M, Szubert AJ, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Comparative Study
- Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIV.
Tsirizani L, Mohsenian Naghani S, Waalewijn H, et al. · J Antimicrob Chemother 2024 · Research Support, Non-U.S. Gov't, Randomized Controlled Trial
- Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C, Molina JM, Cahn P, et al. · Lancet HIV 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Coronary Microcirculatory Dysfunction in People With HIV and Its Association With Antiretroviral Therapy.
Huck DM, Weber B, Parks S, et al. · J Am Heart Assoc 2023 · Clinical Trial, Phase III, Research Support, N.I.H., Extramural
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.